Approval · Notice of Compliance 31071 · 2023
MAYZENT: Notice of Compliance 31071
Issued June 28, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31071
- Date
- June 28, 2023
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety update relying on clinical trial data from study A2130 related to non-live attenuated vaccination and CYP2C9 less frequent alleles.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MAYZENT | Not yet assigned | — |